Cannabinoid Medication for Adults With OCD

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG

Nabilone

"Nabilone is a synthetic cannabinoid that is thought to be a Cannabinoid receptor type 1 (CB 1) agonist. It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."

BEHAVIORAL

Exposure and Response Prevention Therapy

Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions.

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
lead

New York State Psychiatric Institute

OTHER

NCT02911324 - Cannabinoid Medication for Adults With OCD | Biotech Hunter | Biotech Hunter